Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Biostrophin Stories

2012-12-06 08:27:06

SOUTH PLAINFIELD, N.J., Dec. 6, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) seeking conditional approval for ataluren, an investigational new drug for the treatment of patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). Validation of the MAA confirms that the submission is complete and begins the EMA's Committee for Human Medicinal Products' (CHMP) review...

2012-09-27 06:29:05

University of Alberta Professor to be Given Grant to Continue Potentially Groundbreaking Work in Duchenne Muscular Dystrophy HACKENSACK, N.J., Sept. 27, 2012 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) announced today that it will award the University of Alberta's Toshifumi Yokota, Ph.D. a $50,000 grant to continue his work in exon skipping as a potential therapy for Duchenne muscular dystrophy. Dr. Yokota is the Assistant Professor and Research Chair in...

2012-09-17 06:28:41

Dongsheng Duan, Ph.D. to be Given Grant to Continue Work With SERCA2a in Duchenne Muscular Dystrophy HACKENSACK, N.J., Sept. 17, 2012 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) announced today that it will award the University of Missouri's Dongsheng Duan, Ph.D. a $280,000 grant to continue his work to treat cardiomyopathy in Duchenne muscular dystrophy through a gene therapy approach. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO) Dr. Duan...

2012-06-27 02:27:17

SOUTH PLAINFIELD, N.J., June 27, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the initiation of an open-label study in the European Union, Israel, Australia and Canada for patients with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who received ataluren in a prior, PTC-sponsored clinical study. The primary objective of this study is to gain further information on the long-term safety and tolerability of ataluren, an investigational new drug. PTC launched a...

2012-06-22 11:52:36

'A Molecular Bandage for Diseased Muscle' appears today in prestigious Science publication Leading muscular dystrophy researcher Dean Burkin, of the University of Nevada School of Medicine summarizes the impact of a new protein therapeutic, MG53, for the treatment of Duchenne muscular dystrophy in an article published this week in Science Translational Medicine. "This is a focus article in which we summarize the impact of MG53 protein therapy as a treatment option and discuss the...

2012-02-27 10:53:00

Parent Project Muscular Dystrophy Holds 13th Annual Advocacy Conference WASHINGTON, Feb. 27, 2012 /PRNewswire-USNewswire/ -- Nearly 80 parents, grandparents, and relatives of boys with the most common form of muscular dystrophy will be on Capitol Hill today and tomorrow urging Members of Congress to support critical research and patient care initiatives. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO ) Advocates from 23 states are participating in the...

2012-02-21 11:00:00

Grant Funds Work of Tivorsan Pharmaceuticals' Team to Bring Recombinant Biglycan to the Clinic for the Possible Treatment of Duchenne Muscular Dystrophy HACKENSACK, N.J., Feb. 21, 2012 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) announced today that it will award Tivorsan Pharmaceuticals (Tivorsan) a $500,000 grant to develop the company's biglycan therapeutic candidate for Duchenne muscular dystrophy. (Logo:...

2011-12-19 11:22:00

TUCSON, Ariz., Dec. 19, 2011 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association (MDA) has awarded $750,000 to Summit PLC, a UK biotechnology company, to continue development of an experimental drug that may become a viable treatment for boys with Duchenne muscular dystrophy (DMD). The funding comes from MDA Venture Philanthropy (MVP), a part of MDA's translational research program. DMD is one of nine types of muscular dystrophy, a group of genetic, degenerative diseases primarily...

2011-10-27 11:30:00

Naperville's Karlin Family Continues Fight to End Duchenne on Behalf of Son NAPERVILLE, Ill. Oct. 27, 2011 /PRNewswire-USNewswire/ --Marty Karlin, a board member of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced today that his foundation, Rally for Ryan, will host its third annual Gala Event & Raffle at the White Eagle Golf Club in Naperville, Illinois on...

2011-09-22 13:19:00

Largest National Duchenne Organization Gives $98,000 for Bridge Funding HACKENSACK, N.J., Sept. 22, 2011 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced that it has awarded Tejvir S. Khurana, MD, PhD, Professor of Physiology at the University of Pennsylvania and Pennsylvania Muscle Institute an End Duchenne Grant for $98,000. (Logo:...